Search

Your search keyword '"Meijer Sybren L"' showing total 645 results
Start Over Author "Meijer Sybren L"
645 results on '"Meijer Sybren L"'

1. The pluripotency factor NANOG contributes to mesenchymal plasticity and is predictive for outcome in esophageal adenocarcinoma

Author

van der Zalm, Amber P., Dings, Mark P. G., Manoukian, Paul, Boersma, Hannah, Janssen, Reimer, Bailey, Peter, Koster, Jan, Zwijnenburg, Danny, Volckmann, Richard, Bootsma, Sanne, Waasdorp, Cynthia, van Mourik, Monique, Blangé, Dionne, van den Ende, Tom, Oyarce, César I., Derks, Sarah, Creemers, Aafke, Ebbing, Eva A., Hooijer, Gerrit K., Meijer, Sybren L., van Berge Henegouwen, Mark I., Medema, Jan Paul, van Laarhoven, Hanneke W. M., and Bijlsma, Maarten F.

Published
2024
Full Text
View/download PDF

5. Murine CD4+CD25- cells activated in vitro with PMA/ionomycin and anti-CD3 acquire regulatory function and ameliorate experimental colitis in vivo

Author

Majowicz Anna, van der Marel Sander, te Velde Anje A, Meijer Sybren L, Petry Harald, van Deventer Sander J, and Ferreira Valerie

Subjects
IBD, CD45RB transfer, Treg, PMA/ionomycin, Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Abstract Background Induced regulatory T (iTreg) lymphocytes show promise for application in the treatment of allergic, autoimmune and inflammatory disorders. iTreg cells demonstrate advantages over natural Treg (nTreg) cells in terms of increased number of starting population and greater potential to proliferate. Different activation methods to generate iTreg cells result in iTreg cells that are heterogeneous in phenotype and mechanisms of suppression. Therefore it is of interest to explore new techniques to generate iTreg cells and to determine their physiological relevance. Methods Using phorbol myristate acetate (PMA)/ionomycin and anti-CD3 activation of CD4+CD25- cells we generated in vitro functional CD4+CD25+ iTreg (TregPMA) cells. Functionality of the generated TregPMA cells was tested in vivo in a mouse model of inflammatory bowel disease (IBD) - CD45RB transfer colitis model. Results TregPMA cells expressed regulatory markers and proved to ameliorate the disease phenotype in murine CD45RB transfer colitis model. The body weight loss and disease activity scores for TregPMA treated mice were reduced when compared to diseased control group. Histological assessment of colon sections confirmed amelioration of the disease phenotype. Additionally, cytokine analysis showed decreased levels of proinflammatory colonic and plasma IL-6, colonic IL-1 β and higher levels of colonic IL-17 when compared to diseased control group. Conclusions This study identifies a new method to generate in vitro iTreg cells (TregPMA cells) which physiological efficacy has been demonstrated in vivo.

Published
2012
Full Text
View/download PDF

11. Analysis of metastases rates during follow-up after endoscopic resection of early “high-risk” esophageal adenocarcinoma

Author

Karrenbeld, A., Ooms, A., Huysentruyt, C., ten Kate, F., Moll, F., Kats-Ugurlu, G., van Lijnschoten, I., van de Laan, J., Offerhaus, J., Biermann, K., Seldenrijk, K., Brosens, L., Meijer, S., Doukas, M., Nieuwenhuis, Esther A., van Munster, Sanne N., Meijer, Sybren L., Brosens, Lodewijk A.A., Jansen, Marnix, Weusten, Bas L.A. M., Alvarez Herrero, Lorenza, Alkhalaf, Alaa, Schenk, Ed, Schoon, Erik J., Curvers, Wouter L., Koch, Arjun D., van de Ven, Steffi E.M., Verheij, Eva P.D., Nagengast, Wouter B., Westerhof, Jessie, Houben, Martin H.M. G., Tang, Thjon, Bergman, Jacques J.G. H.M., and Pouw, Roos E.

Published
2022
Full Text
View/download PDF

16. Prospective development and validation of a volumetric laser endomicroscopy computer algorithm for detection of Barrett’s neoplasia

Author

Struyvenberg, Maarten R., de Groof, Albert J., Fonollà, Roger, van der Sommen, Fons, de With, Peter H.N., Schoon, Erik J., Weusten, Bas L.A.M., Leggett, Cadman L., Kahn, Allon, Trindade, Arvind J., Ganguly, Eric K., Konda, Vani J.A., Lightdale, Charles J., Pleskow, Douglas K., Sethi, Amrita, Smith, Michael S., Wallace, Michael B., Wolfsen, Herbert C., Tearney, Gary J., Meijer, Sybren L., Vieth, Michael, Pouw, Roos E., Curvers, Wouter L., and Bergman, Jacques J.

Published
2021
Full Text
View/download PDF

19. Tumor immune microenvironmental characteristics in Human Epidermal Growth Factor-2 (HER2) positive esophageal adenocarcinoma: A comparative analysis and biomarker study

Author

MS Medische Oncologie, Cancer, Stroes, Charlotte I, Meijer, Sybren L, Creemers, Geert-Jan, Hooijer, Gerrit K J, Mohammad, Nadia Haj, Los, Maartje, Slingerland, Marije, Hospers, Geke A P, Cats, Annemieke, Beerepoot, Laurens V, Bijlsma, Maarten F, van Laarhoven, Hanneke W M, MS Medische Oncologie, Cancer, Stroes, Charlotte I, Meijer, Sybren L, Creemers, Geert-Jan, Hooijer, Gerrit K J, Mohammad, Nadia Haj, Los, Maartje, Slingerland, Marije, Hospers, Geke A P, Cats, Annemieke, Beerepoot, Laurens V, Bijlsma, Maarten F, and van Laarhoven, Hanneke W M

Published
2024

20. Vertical tumor-positive resection margins and the risk of residual neoplasia after endoscopic resection of Barrett's neoplasia:a nationwide cohort with pathology reassessment

Author

van Tilburg, Laurelle, Verheij, Eva P.D., van de Ven, Steffi E.M., van Munster, Sanne N., Weusten, Bas L.A.M., Herrero, Lorenza Alvarez, Nagengast, Wouter B., Schoon, Erik J., Alkhalaf, Alaa, Bergman, Jacques J.G.H.M., Pouw, Roos E., Oudijk, Lindsey, Meijer, Sybren L., Jansen, Marnix, Doukas, Michail, Koch, Arjun D., van Tilburg, Laurelle, Verheij, Eva P.D., van de Ven, Steffi E.M., van Munster, Sanne N., Weusten, Bas L.A.M., Herrero, Lorenza Alvarez, Nagengast, Wouter B., Schoon, Erik J., Alkhalaf, Alaa, Bergman, Jacques J.G.H.M., Pouw, Roos E., Oudijk, Lindsey, Meijer, Sybren L., Jansen, Marnix, Doukas, Michail, and Koch, Arjun D.

Abstract

BACKGROUND: This study evaluated the proportion of patients with residual neoplasia after endoscopic resection (ER) for Barrett's neoplasia with confirmed tumor-positive vertical resection margin (R1v). METHODS: This retrospective cohort study included patients undergoing ER for Barrett's neoplasia with histologically documented R1v since 2008 in the Dutch Barrett Expert Centers. We defined R1v as cancer cells touching vertical resection margins and Rx as nonassessable margins. Reassessment of R1v specimens was performed by experienced pathologists until consensus was reached regarding vertical margins. RESULTS: 101/110 included patients had macroscopically complete resections (17 T1a, 84 T1b), and 99/101 (98%) ER specimens were histologically reassessed, with R1v confirmed in 74 patients (75%), Rx in 16%, and R0 in 9%. Presence/absence of residual neoplasia could be assessed in 66/74 patients during endoscopic reassessment (52) and/or in the surgical resection specimen (14), and 33/66 (50%) had residual neoplasia. Residual neoplasia detected during endoscopy was always endoscopically visible and biopsies from a normal-appearing ER scar did not detect additional neoplasia. Of 25 patients who underwent endoscopic follow-up (median 37 months [interquartile range 12-50]), 4 developed local recurrence (16.0%), all detected as visible abnormalities. CONCLUSIONS: After ER with R1v, 50% of patients had no residual neoplasia. Histological evaluation of ER margins appears challenging, as in this study 75% of documented R1v cases were confirmed during reassessment. Endoscopic reassessment 8-12 weeks after ER seems to accurately detect residual neoplasia and can help to determine the most appropriate strategy for patients with R1v.

Published
2024

21. Prognostic value of Mandard score and nodal status for recurrence patterns and survival after multimodal treatment of oesophageal adenocarcinoma

Author

Henckens, Sofie P.G., Liu, Dajia, Gisbertz, Suzanne S., Kalff, Marianne C., Anderegg, Maarten C.J., Crull, David, Daams, Freek, van Dalsen, Annette D., Dekker, Jan Willem T., van Det, Marc J., van Duijvendijk, Peter, Eshuis, Wietse J., Groenendijk, Richard P.R., Haveman, Jan Willem, van Hillegersberg, Richard, Luyer, Misha D.P., Olthof, Pim B., Pierie, Jean Pierre E.N., Plat, Victor D., Rosman, Camiel, Ruurda, Jelle P., van Sandick, Johanna W., Sosef, Meindert N., Voeten, Daan M., Vijgen, Guy H.E.J., Bijlsma, Maarten F., Meijer, Sybren L., Hulshof, Maarten C.C.M., Oyarce, Cesar, Lagarde, Sjoerd M., van Laarhoven, Hanneke W.M., van Berge Henegouwen, Mark I., Henckens, Sofie P.G., Liu, Dajia, Gisbertz, Suzanne S., Kalff, Marianne C., Anderegg, Maarten C.J., Crull, David, Daams, Freek, van Dalsen, Annette D., Dekker, Jan Willem T., van Det, Marc J., van Duijvendijk, Peter, Eshuis, Wietse J., Groenendijk, Richard P.R., Haveman, Jan Willem, van Hillegersberg, Richard, Luyer, Misha D.P., Olthof, Pim B., Pierie, Jean Pierre E.N., Plat, Victor D., Rosman, Camiel, Ruurda, Jelle P., van Sandick, Johanna W., Sosef, Meindert N., Voeten, Daan M., Vijgen, Guy H.E.J., Bijlsma, Maarten F., Meijer, Sybren L., Hulshof, Maarten C.C.M., Oyarce, Cesar, Lagarde, Sjoerd M., van Laarhoven, Hanneke W.M., and van Berge Henegouwen, Mark I.

Abstract

BACKGROUND: This study evaluated the association of pathological tumour response (tumour regression grade, TRG) and a novel scoring system, combining both TRG and nodal status (TRG-ypN score; TRG1-ypN0, TRG>1-ypN0, TRG1-ypN+ and TRG>1-ypN+), with recurrence patterns and survival after multimodal treatment of oesophageal adenocarcinoma. METHODS: This Dutch nationwide cohort study included patients treated with neoadjuvant chemoradiotherapy followed by oesophagectomy for distal oesophageal or gastro-oesophageal junctional adenocarcinoma between 2007 and 2016. The primary endpoint was the association of Mandard score and TRG-ypN score with recurrence patterns (rate, location, and time to recurrence). The secondary endpoint was overall survival. RESULTS: Among 2746 inclusions, recurrence rates increased with higher Mandard scores (TRG1 30.6%, TRG2 44.9%, TRG3 52.9%, TRG4 61.4%, TRG5 58.2%; P < 0.001). Among patients with recurrent disease, the distribution (locoregional versus distant) was the same for the different TRG groups. Patients with TRG1 developed more brain recurrences (17.7 versus 9.8%; P = 0.001) and had a longer mean overall survival (44 versus 35 months; P < 0.001) than those with TRG>1. The TRG>1-ypN+ group had the highest recurrence rate (64.9%) and worst overall survival (mean 27 months). Compared with the TRG>1-ypN0 group, patients with TRG1-ypN+ had a higher risk of recurrence (51.9 versus 39.6%; P < 0.001) and worse mean overall survival (33 versus 41 months; P < 0.001). CONCLUSION: Improved tumour response to neoadjuvant therapy was associated with lower recurrence rates and higher overall survival rates. Among patients with recurrent disease, TRG1 was associated with a higher incidence of brain recurrence than TRG>1. Residual nodal disease influenced prognosis more negatively than residual disease at the primary tumour site.

Published
2024

24. Stromal-derived interleukin 6 drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma

Author

Ebbing, Eva A., van der Zalm, Amber P., Steins, Anne, Creemers, Aafke, Hermsen, Simone, Rentenaar, Rosa, Klein, Michelle, Waasdorp, Cynthia, Hooijer, Gerrit K. J., Meijer, Sybren L., Krishnadath, Kausilia K., Punt, Cornelis J. A., van Berge Henegouwen, Mark I., Gisbertz, Suzanne S., van Delden, Otto M., Hulshof, Maarten C. C. M., Medema, Jan Paul, van Laarhoven, Hanneke W. M., and Bijlsma, Maarten F.

Published
2019

25. Vertical tumor-positive resection margins and the risk of residual neoplasia after endoscopic resection of Barrett's neoplasia: a nationwide cohort with pathology reassessment.

Author

van Tilburg, Laurelle, Verheij, Eva P. D., van de Ven, Steffi E. M., van Munster, Sanne N., Weusten, Bas L. A. M., Herrero, Lorenza Alvarez, Nagengast, Wouter B., Schoon, Erik J., Alkhalaf, Alaa, Bergman, Jacques J. G. H. M., Pouw, Roos E., Oudijk, Lindsey, Meijer, Sybren L., Jansen, Marnix, Doukas, Michail, Koch, Arjun D., Brosens, Lodewijk A. A., Curvers, Wouter L., Houben, Martin H. M. G., and de Jonge, Pieter Jan F.

Subjects
ENDOSCOPIC surgery, SURGICAL margin, SURGICAL excision, CANCER cells, TUMORS
Abstract

Background This study evaluated the proportion of patients with residual neoplasia after endoscopic resection (ER) for Barrett's neoplasia with confirmed tumor-positive vertical resection margin (R1v). Methods This retrospective cohort study included patients undergoing ER for Barrett's neoplasia with histologically documented R1v since 2008 in the Dutch Barrett Expert Centers. We defined R1v as cancer cells touching vertical resection margins and Rx as nonassessable margins. Reassessment of R1v specimens was performed by experienced pathologists until consensus was reached regarding vertical margins. Results 101/110 included patients had macroscopically complete resections (17 T1a, 84 T1b), and 99/101 (98%) ER specimens were histologically reassessed, with R1v confirmed in 74 patients (75%), Rx in 16%, and R0 in 9%. Presence/absence of residual neoplasia could be assessed in 66/74 patients during endoscopic reassessment (52) and/or in the surgical resection specimen (14), and 33/66 (50%) had residual neoplasia. Residual neoplasia detected during endoscopy was always endoscopically visible and biopsies from a normal-appearing ER scar did not detect additional neoplasia. Of 25 patients who underwent endoscopic follow-up (median 37 months [interquartile range 12–50]), 4 developed local recurrence (16.0%), all detected as visible abnormalities. Conclusions After ER with R1v, 50% of patients had no residual neoplasia. Histological evaluation of ER margins appears challenging, as in this study 75% of documented R1v cases were confirmed during reassessment. Endoscopic reassessment 8–12 weeks after ER seems to accurately detect residual neoplasia and can help to determine the most appropriate strategy for patients with R1v. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Active Surveillance Versus Immediate Surgery in Clinically Complete Responders After Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Propensity Matched Study

Author

van der Wilk, Berend J., Noordman, Bo J., Neijenhuis, Lisanne K. A., Nieboer, Daan, Nieuwenhuijzen, Grard A. P., Sosef, Meindert N., van Berge Henegouwen, Mark I., Lagarde, Sjoerd M., Spaander, Manon C. W., Valkema, Roelf, Biermann, Katharina, Wijnhoven, Bas P. L., van der Gaast, Ate, van Lanschot, J. Jan B., Doukas, Michael, Nikkessen, Suzan, Luyer, Misha, Schoon, Erik J., Roef, Mark J., van Lijnschoten, Ineke, Oostenbrug, Liekele E., Riedl, Robert G., Gisbertz, Suzanne S., Krishnadath, Kausilia K., Bennink, Roel J., and Meijer, Sybren L.

Published
2021
Full Text
View/download PDF

27. microRNA 125a Regulates MHC-I Expression on Esophageal Adenocarcinoma Cells, Associated With Suppression of Antitumor Immune Response and Poor Outcomes of Patients

Author

Mari, Luigi, Hoefnagel, Sanne J.M., Zito, Domenico, van de Meent, Marian, van Endert, Peter, Calpe, Silvia, Sancho Serra, Maria del Carmen, Heemskerk, Mirjam H.M., van Laarhoven, Hanneke W.M., Hulshof, Maarten C.C.M., Gisbertz, Susanne S., Medema, Jan Paul, van Berge Henegouwen, Mark I., Meijer, Sybren L., Bergman, Jacques J.G.H.M., Milano, Francesca, and Krishnadath, Kausilia K.

Published
2018
Full Text
View/download PDF

28. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study

Author

Doukas, Michael, Krak, Nanda C, Poley, Jan-Werner, van Rij, Caroline M, Bergman, Jaques JGHM, Gisbertz, Suzanne S, van Laarhoven, Hanneke WM, Meijer, Sybren L, Goense, Lucas, Haj Mohammad, Nadia, Hobbelink, Monique GG, Offerhaus, G Johan A, Vleggaar, Frank, Curvers, Wouter L, Creemers, Geert-Jan, Roef, Mark J, van der Sangen, Maurice JC, Buijsen, Jeroen, Riedl, Robert G, Schreurs, Wendy MJ, Warmerdam, Fabienne ARM, Janssen, MJR, van der Post, Chella, Radema, Sandra A, Rosman, Camiel, Rütten, Heidi, Noordman, Bo Jan, Spaander, Manon C W, Valkema, Roelf, Wijnhoven, Bas P L, van Berge Henegouwen, Mark I, Shapiro, Joël, Biermann, Katharina, van der Gaast, Ate, van Hillegersberg, Richard, Hulshof, Maarten C C M, Krishnadath, Kausilia K, Lagarde, Sjoerd M, Nieuwenhuijzen, Grard A P, Oostenbrug, Liekele E, Siersema, Peter D, Schoon, Erik J, Sosef, Meindert N, Steyerberg, Ewout W, and van Lanschot, J Jan B

Published
2018
Full Text
View/download PDF

42. Distribution of lymph node metastases in esophageal carcinoma [TIGER study]: study protocol of a multinational observational study

Author

Hagens, Eliza R. C., van Berge Henegouwen, Mark I., van Sandick, Johanna W., Cuesta, Miguel A., van der Peet, Donald L., Heisterkamp, Joos, Nieuwenhuijzen, Grard A. P., Rosman, Camiel, Scheepers, Joris J. G., Sosef, Meindert N., van Hillegersberg, Richard, Lagarde, Sjoerd M., Nilsson, Magnus, Räsänen, Jari, Nafteux, Philippe, Pattyn, Piet, Hölscher, Arnulf H., Schröder, Wolfgang, Schneider, Paul M., Mariette, Christophe, Castoro, Carlo, Bonavina, Luigi, Rosati, Riccardo, de Manzoni, Giovanni, Mattioli, Sandro, Garcia, Josep Roig, Pera, Manuel, Griffin, Michael, Wilkerson, Paul, Chaudry, M. Asif, Sgromo, Bruno, Tucker, Olga, Cheong, Edward, Moorthy, Krishna, Walsh, Thomas N., Reynolds, John, Tachimori, Yuji, Inoue, Haruhiro, Matsubara, Hisahiro, Kosugi, Shin-ichi, Chen, Haiquan, Law, Simon Y. K., Pramesh, C. S., Puntambekar, Shailesh P., Murthy, Sudish, Linden, Philip, Hofstetter, Wayne L., Kuppusamy, Madhan K., Shen, K. Robert, Darling, Gail E., Sabino, Flávio D., Grimminger, Peter P., Meijer, Sybren L., Bergman, Jacques J. G. H. M., Hulshof, Maarten C. C. M., van Laarhoven, Hanneke W. M., Mearadji, Banafsche, Bennink, Roel J., Annema, Jouke T., Dijkgraaf, Marcel G. W., and Gisbertz, Suzanne S.

Published
2019
Full Text
View/download PDF

43. Wide-area transepithelial sampling with computer-assisted analysis to detect high grade dysplasia and cancer in Barrett's esophagus: a multicenter randomized study

Author

van Munster, Sanne N, Leclercq, Philippe, Haidry, Rehan, Messmann, Helmut, Probst, Andreas, Ragunath, Krish, Bhandari, Pradeep, Repici, Alessandro, Munoz-Navas, Miguel, Seewald, Stefan, Lemmers, Arnaud, Fernández-Esparrach, Glòria, Pech, Oliver, Schoon, Erik J, Kariv, Revital, Neuhaus, Horst, Weusten, Bas L A M, Siersema, Peter D, Correale, Loredana, Meijer, Sybren L, de Hertogh, Gert, Bergman, Jacques J G H M, Hassan, Cesare, Bisschops, Raf, van Munster, Sanne N, Leclercq, Philippe, Haidry, Rehan, Messmann, Helmut, Probst, Andreas, Ragunath, Krish, Bhandari, Pradeep, Repici, Alessandro, Munoz-Navas, Miguel, Seewald, Stefan, Lemmers, Arnaud, Fernández-Esparrach, Glòria, Pech, Oliver, Schoon, Erik J, Kariv, Revital, Neuhaus, Horst, Weusten, Bas L A M, Siersema, Peter D, Correale, Loredana, Meijer, Sybren L, de Hertogh, Gert, Bergman, Jacques J G H M, Hassan, Cesare, and Bisschops, Raf

Abstract

BACKGROUND: Current surveillance for Barrett's esophagus (BE), consisting of four-quadrant random forceps biopsies (FBs), has an inherent risk of sampling error. Wide-area transepithelial sampling (WATS) may increase detection of high grade dysplasia (HGD) and esophageal adenocarcinoma (EAC). In this multicenter randomized trial, we aimed to evaluate WATS as a substitute for FB.METHODS: Patients with known BE and a recent history of dysplasia, without visible lesions, at 17 hospitals were randomized to receive either WATS followed by FB or vice versa. All WATS samples were examined, with computer assistance, by at least two experienced pathologists at the CDx Diagnostics laboratory. Similarly, all FBs were examined by two expert pathologists. The primary end point was concordance/discordance for detection of HGD/EAC between the two techniques.RESULTS: 172 patients were included, of whom 21 had HGD/EAC detected by both modalities, 18 had HGD/EAC detected by WATS but missed by FB, and 12 were detected by FB but missed by WATS. The detection rate of HGD/EAC did not differ between WATS and FB (P = 0.36). Using WATS as an adjunct to FB significantly increased the detection of HGD/EAC vs. FB alone (absolute increase 10 % [95 %CI 6 % to 16 %]). Mean procedural times in minutes for FB alone, WATS alone, and the combination were 6.6 (95 %CI 5.9 to 7.1), 4.9 (95 %CI 4.1 to 5.4), and 11.2 (95 %CI 10.5 to 14.0), respectively.CONCLUSIONS: Although the combination of WATS and FB increases dysplasia detection in a population of BE patients enriched for dysplasia, we did not find a statistically significant difference between WATS and FB for the detection of HGD/EAC as single modality.

Published
2023

44. Feasibility and Safety of Tailored Lymphadenectomy Using Sentinel Node-Navigated Surgery in Patients with High-Risk T1 Esophageal Adenocarcinoma

Author

Unit Opleiding Aios, Cancer, MS MDL 1, MS Radiologie, Pathologie Pathologen staf, MS CGO, Frederiks, Charlotte N, Overwater, Anouk, Bergman, Jacques J G H M, Pouw, Roos E, de Keizer, Bart, Bennink, Roel J, Brosens, Lodewijk A A, Meijer, Sybren L, van Hillegersberg, Richard, van Berge Henegouwen, Mark I, Ruurda, Jelle P, Gisbertz, Suzanne S, Weusten, Bas L A M, Unit Opleiding Aios, Cancer, MS MDL 1, MS Radiologie, Pathologie Pathologen staf, MS CGO, Frederiks, Charlotte N, Overwater, Anouk, Bergman, Jacques J G H M, Pouw, Roos E, de Keizer, Bart, Bennink, Roel J, Brosens, Lodewijk A A, Meijer, Sybren L, van Hillegersberg, Richard, van Berge Henegouwen, Mark I, Ruurda, Jelle P, Gisbertz, Suzanne S, and Weusten, Bas L A M

Published
2023

46. Supplementary Data from Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT)

Author

van den Ende, Tom, primary, de Clercq, Nicolien C., primary, van Berge Henegouwen, Mark I., primary, Gisbertz, Suzanne S., primary, Geijsen, E.D., primary, Verhoeven, R.H.A., primary, Meijer, Sybren L., primary, Schokker, Sandor, primary, Dings, M.P.G., primary, Bergman, Jacques J.G.H.M., primary, Haj Mohammad, Nadia, primary, Ruurda, Jelle P., primary, van Hillegersberg, Richard, primary, Mook, Stella, primary, Nieuwdorp, Max, primary, de Gruijl, Tanja D., primary, Soeratram, Tanya T.D., primary, Ylstra, Bauke, primary, van Grieken, Nicole C.T., primary, Bijlsma, Maarten F., primary, Hulshof, Maarten C.C.M., primary, and van Laarhoven, H.W.M., primary

Published
2023
Full Text
View/download PDF

47. Figure from Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT)

Author

van den Ende, Tom, primary, de Clercq, Nicolien C., primary, van Berge Henegouwen, Mark I., primary, Gisbertz, Suzanne S., primary, Geijsen, E.D., primary, Verhoeven, R.H.A., primary, Meijer, Sybren L., primary, Schokker, Sandor, primary, Dings, M.P.G., primary, Bergman, Jacques J.G.H.M., primary, Haj Mohammad, Nadia, primary, Ruurda, Jelle P., primary, van Hillegersberg, Richard, primary, Mook, Stella, primary, Nieuwdorp, Max, primary, de Gruijl, Tanja D., primary, Soeratram, Tanya T.D., primary, Ylstra, Bauke, primary, van Grieken, Nicole C.T., primary, Bijlsma, Maarten F., primary, Hulshof, Maarten C.C.M., primary, and van Laarhoven, H.W.M., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results